Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

In another note of news, a key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's ( NVO) Wegovy (semaglutide) and Eli Lilly's ( LLY) Zepbound ...

Enter efimosfermin alfa, described as a phase 3-ready, once-monthly injectable fibroblast growth factor 21 (FGF21) analogue with potential across steatotic liver diseases (SLD), including MASH and ...

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals' lead pipeline candidate, efimosfermin alfa ...

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals’ lead pipeline candidate, efimosfermin alfa ...

Shares of Akero Therapeutics (NASDAQ:AKRO) climbed on Tuesday after StreetInsider reported that the San Francisco, California ...

Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller ...